Department of Internal Medicine, NorthShore University Healthsystem, Evanston, IL 60201, USA.
Oncol Rep. 2011 Nov;26(5):1127-32. doi: 10.3892/or.2011.1395. Epub 2011 Jul 18.
This study was undertaken to examine the gender-sensitivity and chemopreventive responsiveness of celecoxib on intestinal stem-like cells as a biomarker of colon carcino-genesis, using the MIN mouse model. Male and female MIN mice (6-7-weeks old) were randomized to either control diet or to a diet supplemented with celecoxib (1,500 ppm). The animals were euthanized ten weeks later and the intestines were flushed and opened longitudinally to assess tumor count. Small intestinal segments were formalin-fixed and tissue sections were subjected to immunohistochemical evaluation of DCAMKL1, a known marker of stem-like cells. We found that in animals receiving control (AIN 76A diet) alone, female MIN mice had a higher polyp count than males (52.32 ± 13.89 vs. 35.43 ± 16.05; p<0.0005). However, compared to control diet groups, celecoxib supplementation caused a larger reduction in the number of polyps in females than their male cohorts (6.38 ± 1.43 vs. 12.83 ± 6.74; a reduction of 88% in females to 64% in males). Significant differences (p=0.013) were observed in the number of DCAMKL1-stained cells in the crypts of the wild-type (WT) (10.01 ± 1.07 stem cells per high powered field; HPF) compared to the MIN mice (24.15 ± 8.08 stem cells per HPF), illustrating increased stem-like cells in animals that are more prone to neoplasia. DCAMKL1 labeled stem-like cells were equal in number in the male and female groups receiving the control AIN 76A diet alone (females, 25.73 stem-like cells/HPF); males, 24.15 stem-like cells/HPF). However, females showed a greater reduction in the number of DCAMKL1-labeled stem-like cells with celecoxib supplementation than the respective males (16.63 ± 4.23 vs. 21.56 ± 9.06; a reduction of 35.4% in females to 10.7% in males). We conclude that a higher number of stem-like cells in the uninvolved mucosa paralleled tumorigenesis and mirrored greater chemopreventive responsiveness of female MIN mice compared to males.
这项研究旨在使用 MIN 小鼠模型,研究塞来昔布对肠道类器官样细胞的性别敏感性和化学预防反应,作为结肠癌发生的生物标志物。雄性和雌性 MIN 小鼠(6-7 周龄)被随机分配到对照组饮食或补充塞来昔布(1500ppm)的饮食组。十周后,处死动物,冲洗肠道并纵向打开以评估肿瘤数量。用福尔马林固定小肠段,组织切片进行 DCAMKL1 的免疫组织化学评估,DCAMKL1 是类器官样细胞的已知标志物。我们发现,单独接受对照(AIN 76A 饮食)的动物中,雌性 MIN 小鼠的息肉数量高于雄性(52.32 ± 13.89 比 35.43 ± 16.05;p<0.0005)。然而,与对照组相比,塞来昔布补充剂在雌性动物中引起的息肉数量减少幅度大于雄性(6.38 ± 1.43 比 12.83 ± 6.74;雌性减少 88%,雄性减少 64%)。在野生型(WT)(每个高倍视野 10.01 ± 1.07 个干细胞)和 MIN 小鼠(每个高倍视野 24.15 ± 8.08 个干细胞)的隐窝中,观察到 DCAMKL1 染色细胞数量的显著差异(p=0.013),表明在更易发生肿瘤的动物中,干细胞样细胞增加。单独接受对照 AIN 76A 饮食的雄性和雌性组中,DCAMKL1 标记的干细胞样细胞数量相等(雌性,25.73 个干细胞/HPF;雄性,24.15 个干细胞/HPF)。然而,与相应的雄性相比,雌性在补充塞来昔布后,DCAMKL1 标记的干细胞样细胞数量减少更多(16.63 ± 4.23 比 21.56 ± 9.06;雌性减少 35.4%,雄性减少 10.7%)。我们得出结论,未受累黏膜中更多的干细胞样细胞与肿瘤发生平行,并反映了雌性 MIN 小鼠比雄性具有更高的化学预防反应性。